SATSUMA PHARMACEUTICALS, INC. (STSA): Price and Financial Metrics

SATSUMA PHARMACEUTICALS, INC. (STSA): $1.10

0.01 (-0.90%)

POWR Rating

Component Grades

Momentum

B

Stability

D

Sentiment

Quality

C

Add STSA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#140 of 382

in industry

STSA Price/Volume Stats

Current price $1.10 52-week high $8.08
Prev. close $1.11 52-week low $0.59
Day low $1.01 Volume 1,829,700
Day high $1.14 Avg. volume 701,788
50-day MA $0.97 Dividend yield N/A
200-day MA $2.38 Market Cap 36.47M

STSA Stock Price Chart Interactive Chart >


SATSUMA PHARMACEUTICALS, INC. (STSA) Company Bio


Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.


STSA Latest News Stream


Event/Time News Detail
Loading, please wait...

STSA Latest Social Stream


Loading social stream, please wait...

View Full STSA Social Stream

Latest STSA News From Around the Web

Below are the latest news stories about SATSUMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate STSA as an investment opportunity.

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine

January 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache SocietyUnlike current DHE products, STS101 is designed to be easy-to-carry, quick and easy to self-administer within seconds without need for involved administration procedures and to rapidly achieve high drug plasma lev

Yahoo | May 18, 2023

Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology’s (AAN) 75th Annual Meeting. The 2023 meeting will be held in a hybrid virtual and in-p

Yahoo | April 21, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning!

William White on InvestorPlace | April 17, 2023

Why Is Prometheus Biosciences (RXDX) Stock Up 70% Today?

Prometheus Biosciences (RXDX) stock is on the rise Monday after the company revealed a $10.8 billion acquisition deal with Merck (MRK).

William White on InvestorPlace | April 17, 2023

Why Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?

Satsuma Pharmaceuticals (STSA) stock is taking off on Monday after revealing an acquisition deal with Shin Nippon Biomedical Laboratories.

William White on InvestorPlace | April 17, 2023

Read More 'STSA' Stories Here

STSA Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 54.34%
3-year -80.87%
5-year N/A
YTD N/A
2023 0.00%
2022 -80.00%
2021 -2.39%
2020 -76.58%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!